Atyr Pharma Inc. (NASDAQ:LIFE) shares fell 2.4% during mid-day trading on Tuesday . The stock traded as low as $3.15 and last traded at $3.22, with a volume of 69,364 shares traded. The stock had previously closed at $3.30.

Several research firms have issued reports on LIFE. Zacks Investment Research upgraded shares of Atyr Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. BMO Capital Markets restated a “hold” rating on shares of Atyr Pharma in a report on Thursday, May 12th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Atyr Pharma has an average rating of “Hold” and an average price target of $23.75.

The firm’s 50 day moving average is $2.91 and its 200-day moving average is $3.79. The company’s market capitalization is $72.96 million.

Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. Equities research analysts expect that Atyr Pharma Inc. will post ($2.79) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Atyr Pharma stock. RS Investment Management Co. LLC boosted its stake in Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned approximately 5.10% of Atyr Pharma worth $11,857,000 at the end of the most recent reporting period.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.